The potential of chitosan for the oral administration of peptides

Expert Opinion on Drug Delivery

Volumn 2, Issue 5, 2005, Pages 843-854

  Prego, Cecilia ^a   Torres, Dolores ^a   Alonso, Maria Jose ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chitosan; Delivery systems; Oral administration; Peptides proteins

Indexed keywords

ACRYLIC ACID; BOVINE SERUM ALBUMIN; BUSERELIN; CALCITONIN; CELLULOSE; CHITIN; CHITOSAN; CYCLOSPORIN A; DRUG VEHICLE; ELCATONIN; ENZYME INHIBITOR; HORSERADISH PEROXIDASE; INSULIN; INULIN; LIPOSOME; MACROGOL; MANNAN; MANNITOL; MICROSPHERE; NANOCAPSULE; NANOPARTICLE; PENETRATION ENHANCING AGENT; PEPTIDE; POLYMER; POLYSACCHARIDE; PROTEIN; SALCATONIN; TETANUS TOXOID; TRIPALMITIN; TRIPOLYPHOSPHATE; UNINDEXED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STRUCTURE; DRUG USE; HUMAN; MACROMOLECULE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CARBOHYDRATE SEQUENCE; CHITOSAN; EXCIPIENTS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 27144541896     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.5.843     Document Type: Review

References (91)

1. ROUGET C: Des substances amylacées dans le tissu des animaux, spécialement les articulés (chitine). Comp. Rend. (1859) 48:792-795.
2. SUGANO M, WATANABE S, KISHI A et al.: Hypocholesterolemic action of chitosans with different viscosities in rats. Lipids (1988) 23:187-191.
3. ALLAN CR, HADWIGER LA: The fungicidal effect of chitosan on fungi of varying cell wall composition. Exp. Micol. (1979) 3:285-287.
4. BALASSA LL, PRUDDEN JF: Application of chitin and chitosan in wound healing acceleration. Proceedings of the First International Conference on Chitin/Chitosan. Cambridge, USA (1978): 269-305.
5. HIRANO S, SEINO H, AKIYAMA I, NONAKA I: Biocompatibility of chitosan by oral and intravenous administration. Polym. Mat. Eng. Sci. (1988) 59:897-901.
6. HIRANO S, SEINO H, AKIYAMA I, NONAKA I: Chitosan: a biocompatible material for oral and intravenous administrations. In: Progress in Biomedical Polymers, CG Gebelein, RL Dunn (Eds.), Plenum Press, New York (1990):283-290.
7. PANGBURN SH, TRESCONY PV, HELLER J: Lysozyme degradation of partially deacetylated chitin, its films and hydrogels. Biomaterials (1982) 3:105-108.
8. ILLUM L: Chitosan and its use as a pharmaceutical excipient. Pharm. Res. (1998) 15:1326-1331.
9. ILLUM L, JABBAL-GILL I, HINCHCLIFFE M, FISHER AN, DAVIS SS: Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. (2001) 51:81-96.
10. FERNANDEZ-URRUSUNO R, ROMANI D, CALVO P, VILA-JATO JL, ALONSO MJ: Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. S.T.P. Pharma Sci. (1999) 9:429-436.
11. FERNANDEZ-URRUSUNO R, CALVO P, REMUÑAN-LOPEZ C, VILA-JATO JL, ALONSO MJ: Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. (1999) 16:1576-1581.
12. VILA A, SANCHEZ A, TOBIO M, CALVO P, ALONSO MJ: Design of biodegradable particles for protein delivery. J. Control. Release (2002) 78:15-24.
13. VILA A, SANCHEZ A, JANES K et al.: Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. (2004) 57:123-131.
14. ILLUM L, DODANE V, IQBAL K: Chitosan technology to enhance the effectiveness of nasal drug delivery. Drug Deliv. Technol. (2002) 2:40-43.
15. DAVIS SS, ILLUM L: Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. (2003) 42:1107-1128.
16. ALONSO MJ, SANCHEZ A: The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. (2003) 55:1451-1463.
17. DE CAMPOS AM, SANCHEZ A, ALONSO MJ: Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. (2001) 224:159-168.
18. DE CAMPOS AM, SANCHEZ A, GREF R, CALVO P, ALONSO MJ: The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur. J. Pharm. Sci. (2003) 20:73-81.
19. DE CAMPOS AM, DIEBOLD Y, CARVALHO ELS, SANCHEZ A, ALONSO MJ: Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. (2004) 21:803-810.
20. PORTERO A, REMUÑAN-LOPEZ C, VILA-JATO JL: Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine. Int. J. Pharm. (1998) 175:75-84.
21. AYDIN Z, AKBUGA J: Chitosan beads for the delivery of salmon calcitonin: preparation and release characteristics. Int. J. Pharm. (1996) 131:101-103.
22. SINHA VR, SINGLA AK, WADHAWAN R: Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm. (2004) 274:1-33.
23. REMUÑAN-LOPEZ C, PORTERO A, LEMOS M et al.: Chitosan microspheres for the specific delivery of amoxycillin to the gastric cavity. S.T.P. Pharma. Sci. (2000) 10:69-76.
24. BERNKOP-SCHNÜRCH A, HOFFER MH, KAFEDJIISKI: Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin. Drug Deliv. (2004) 1:87-98.
25. VAN DER MERWE SM, VERHOEF JC, VERHEIJDEN JH, KOTZE AF, JUNGINGER HE: Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharm. (2004) 58:225-235.
26. JANES KA, CALVO P, ALONSO MJ: Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. (2001) 47:83-97.
27. RADI HEJAZI, MANSOOR A: Chitosan-based gastrointestinal delivery systems. J. Control. Release (2003) 89:151-165.
28. SINGLA AK, CHAWLA M: Chitosan: some pharmaceutical and biological aspects- an update. J. Pharm. Pharmacol. (2001) 53:1047-1067.
29. ILLUM L: Nasal drug delivery-possibilities, problems and solutions. J. Control. Release (2003) 87:187-198.
30. CHO YW, JANG J, PARK CR, KO SW: Preparation and solubility in acid and water of partially deacetylated chitins. Biomacromolecules (2000) 1:609-614.
31. TSAIH ML, CHEN RH: Effects of ionic strength and pH on the diffusion coefficients and conformation of chitosans molecule in solution. J. Appl. Polym. Sci. (1999) 73:2041-2050.
32. ARTURSSON P, LINDMARK T, DAVIS SS, ILLUM L: Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. (1994) 11:1358-1361.
33. DODANE V, KHAN MA, MERWIN JR: Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. (1999) 182:21-32.
34. SCHIPPER NGM, VARUM KM, ARTURSSON P: Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of the molecular weight and the degree of acetylation on drug transport across human intestinal epithelium (Caco-2) cells. Pharm. Res. (1996) 13:1686-1692.
35. SMITH J, WOOD E, DORNISH M: Effect of chitosan on epithelial cell tight junctions. Pharm. Res. (2004) 21:43-49.
36. KOTZE AF, DE LEEUW BJ, LUESSEN HL et al.: Chitosans for enhanced delivery of therapeutic peptides across the intestinal epithelium: in vitro evaluation in Caco-2 cell monolayers. Int. J. Pharm. (1997) 159:243-253.
37. SMITH JM, DORNISH M, WORD EJ: Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials (2005) 26:3269-3276.
38. LEHR C-M, BOUWSTRA JA, SCHACHT EH, JUNGINGER HE: In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. (1992) 78:43-48.
39. HE P, DAVIS SS, ILLUM L: In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. (1998) 166:75-88.
40. KAWASHIMA Y, YAMAMOTO H, TAKEUCHI H, KUNO Y: Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. (2000) 5:77-85.
41. CARAMELLA CM, ROSSI S, BONFERONI MC: A theological approach to explain the mucoadhesive behavior of polymers hydrogels. In: Encyclopedia of controlled drug delivery (Volume 1). Mathiowit E (Ed.), John Wiley & Sons Inc., New York, NY, USA (1999): 25-65.
42. ARAI K, KINUMAKI T, FUJITA T: Toxicity of chitosan. Bull. Tokai Reg. Fish. Res. Lab. (1968) 43:89-94.
43. KOIDE SS: Chitin-chitosan - properties, benefits and risks. Nutr. Res. (1998) 18:1091-1101.
44. PITTLER MH, ABBOT NC, HARKNESS EF, ERNST E: Randomized, double-blind trial of chitosan for body weight reduction. Eur. J. Clin. Nutr. (1999) 53:379-381.
45. ARTURSSON P: Cell cultures as models for intestinal peptide transport. S.T.P. Pharma Sci. (1993) 3:5-10.
46. LUESSEN HL, RENTEL CO, KOTZE AF et al.: Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosa in vitro. J. Control Release (1997) 45:15-23.
47. LUESSEN HL, DE LEEUW BJ, LANGEMEYER MW et al.: Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. (1996) 13:1668-1672.
48. KOTZE AF, LUESSEN HL, DE LEEUW BJ et al.: Comparison of the effect of different chitosan salts and and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J. Control. Release (1998) 51:35-46.
49. SNYMAN D, HAMMAN JH, KOTZE AF: Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev. Ind. Pharm. (2003) 29:59-67.
50. THANOU M, VERHOEF JC, MARBACH P, JUNGINGER HE: Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J. Pharm. Sci. (2000) 89:951-957.
51. THANOU M, VERHOEF JC, VERHEIJDEN JHM, JUNGINGER HE: Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs. Pharm. Res. (2001) 18:823-828.
52. KOTZE AF, THANOU MM, LUESSEN HL et al.: Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments. J. Pharm. Sci. (1999) 88:253-257.
53. GUGGI D, KAST CE, BERNKOP-SCHNÜRCH A. In vivo evaluation of an oral calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm. Res. (2003) 20:1989-1994.
54. BERNKOP-SCHNÜRCH A, GUGGI D, PINTER Y: Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J. Control. Release (2004) 94:177-186.
55. LANGOTH N, GUGGI D, PINTER Y, BERNKOP-SCHNÜRCH A. Thiolated chitosan: in vitro evaluation of its permeation enhancing properties. Proceedings of the 30th Annual Meeting of the Controlled Release Society, Glasgow, UK (2003):34.
56. KRAULAND HA, GUGGI D, BERNKOP-SCHNÜRCH A. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. J. Control. Release (2004) 95:547-555.
57. YAMAMOTO A, TOZAKI H, OKADA N, FUJITA T: Colon-specific delivery of peptide drugs and anti-inflamatory drugs using chitosan capsules. S.T.P. Pharma Sci. (2000) 10:23-34.
58. SINHA VR, KUMRIA R: Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. (2003) 18:3-18.
59. LAMPRECHT A, YAMAMOTO H, TAKEUCHI H, KAWASHIMA Y: pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J. Control. Release (2004) 98:1-9.
60. TORRES D, RODRIGUEZ M, CUÑA M: Microencapsulated lipid cores for site-specific delivery of corticosteroid and peptide drugs to the colonic region. S.T.P. Pharma Sci. (2003) 13:49-56.
61. LORENZO-LAMOSA ML, REMUÑAN-LOPEZ C, VILA-JATO JL, ALONSO MJ: Design of microencapsulated chitosan microspheres for colonic drug delivery. J. Control. Release (1998) 52:109-118.
62. TOZAKI H, KOMOIKE J, TADA C et al.: Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci. (1997) 86:1016-1021.
63. UCHEGBU IF, SCHATZLEIN AG, TETLEY L et al.: Polymeric chitosan-based vesicles for drug delivery. J. Pharm. Pharmacol. (1998) 50:453-458.
64. KIM K, KWON S, PARK JH, CHUNG H, JEONG SY, ICK CK: Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. Biomacromolecules. (2005) 6:1154-1158.
65. LIU C-G, DESAI KGH, CHEN X-G, PARK H-J: Linolenic acid-modified chitosan for formation of self-assembled nanoparticles. J. Agric. Food Chem. (2005) 53:437-441.
66. OHYA Y, CAI R, NISHIZAWA H, HARA K, OUCHI T: Preparation of PEG-grafted chitosan nanoparticles as peptide drug carriers. S.T.P. Pharma Sci. (2000) 10:77-82.
67. CALVO P, REMUÑAN-LOPEZ C, VILA-JATO JL, ALONSO MJ: Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. (1997) 63:125-132.
68. PAN Y, LI Y, ZHAO H et al.: Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. (2002) 249:139-147.
69. MA Z, LIM TM, LIM LY: Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Pharm. Nanotechnol. (2005) 293:271-280.
70. BEHRENS I, VILA-PENA AI, ALONSO MJ, KISSEL T: Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. (2002) 19:1185-1193.
71. CUÑA M, ALONSO-SANDE M, REMUÑAN-LOPEZ C et al.: Development of chitosan/glucomannan nanoparticles as carriers for oral protein administration. Proceedings of the 29th Annual Meeting of the Controlled Release Society. Seoul, Korea (2002):136.
72. TOMIZAWA H, ARAMAKI Y, FUJII Y et al.: Uptake of phosphatidylserine liposomes by rat Peyer's patches following intraluminal administration. Pharm. Res. (1993) 10:549-552.
73. ALONSO M, TEIJEIRO D, REMUÑAN-LOPEZ C, ALONSO MJ: Chitosan/glucomannan nanoparticles as oral delivery systems for insulin. 2nd Pharmaceutical Sciences World Congress, Kyoto, Japan (2004): 239.
74. EL-SHABOURI MH: Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. (2002) 249:101-108.
75. CALVO P, REMUÑAN-LOPEZ C, VILA-JATO JL, ALONSO MJ: Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsion. Colloid. Polym. Sci. (1997) 275:46-53.
76. PREGO C, GARCIA M, TORRES D, ALONSO MJ: Transmucosal macromolecular drug delivery. J. Control. Release (2005) 101:151-162.
77. PREGO C, FERNANDEZ-MEGIA E, NOVOA-CARBALLAL R et al.: Chitosan and chitosan-PEG nanocapsules: new carriers for improving the oral absorption of calcitonin. Proceedings of the 30th Annual Meeting of the Controlled Release Society, Glasgow, UK (2003): 70.
78. PREGO C, FABRE M, TORRES D, ALONSO MJ: Study of the interaction of chitosan nanocapsules with intestinal model cell lines. 30th Annual Meeting of the Controlled Release Society Miami, FL, USA (2005)
79. GARCIA-FUENTES M, TORRES D, ALONSO MJ: New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm. (2005) 296 (1-2):122-132.
80. GARCIA-FUENTES M, TORRES D, ALONSO MJ: Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid. Surf. B: Biointerf. (2002) 27:159-168.
81. PREGO C, GARCIA-FUENTES M, ALONSO MJ, TORRES D: Chitosan-coated lipid nanoparticles enhance the oral absorption of calcitonin, Proceedings of the 30th Annual Meeting of the Controlled Release Society, Glasgow, UK (2003) 308.
82. GARCIA-FUENTES M, PREGO C, TORRES D, ALONSO MJ: A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. Eur J. Pharm. Sci., (2005) 25:133-143.
83. TAKEUCHI H, YAMAMOTO H, NIWA T, KAWASHIMA Y: Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. (1996) 13:896-901.
84. TAKEUCHI H, MATSUI Y, YAMAMOTO H, KAWASHIMA Y: Mucoadhesive properties of carbopol and chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control Release (2003) 86:235-242.
85. WU Z-H, PING Q-N, WEI Y, LAI J-M: Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharm. Sinica (2004) 25:966-972.
86. SINGH BN, MAJURU S: Oral delivery of therapeutic macromolecules: a perspective using the Eligen™ technology. Drug Del. Technol. (2003) 3:58-62.
87. MAJURU S: Advances in the oral delivery of heparin from solid dosage forms using Emisphere's Eligen® oral drug delivery technology. Drug Del. Technol. (2004) 4:84-89.
88. CLEMENT S, DANDONA P, STILL JG, KOSUTIC G: Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus; results from a Phase I/II clinical trial. Metabolism (2004) 53:54-58.
89. MEHTA NM: Oral delivery and recombinant production of peptide hormones. Part I: making oral delivery possible. BioPharm. Int. (2004) 17:38-43.
90. DAMGE C, HILLAIRE-BUYS D, PUECH R et al.: Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diabetes, Nutr. Metab. (1995) 8:3-9.
91. PEPPAS NA, WOOD KM, BLANCHETTE JO: Hydrogels for oral delivery of therapeutic proteins: Expert Opin. Biol. Ther. (2004) 4:881-887.